Fig. 1.
Mutational landscape of human BRCA1-mutated TNBC and characterization of the WB1P model. a Overview of the most common deleterious mutations and copy-number events in 80 BRCA1-mutated human breast tumor samples from four large-scale tumor-sequencing studies. b Overview of the germline and somatic mouse models for mammary gland-specific inactivation of conditional Brca1 and Trp53 alleles. c Kaplan–Meier curve showing mammary tumor-specific survival for WapCre;Brca1F/F;Trp53F/F (WB1P) female mice. d Representative hematoxylin and eosin (HE) staining and immunohistochemical detection of E-cadherin, vimentin, ER and PR in WB1P tumors and in tumors from Lenti-Cre injected Brca1F/F;Trp53F/F (B1P) mice. Bar, 400 µm. e Kaplan–Meier curve showing mammary tumor-specific survival of B1P females injected with Lenti-Cre. f Unsupervised clustering (Euclidean distance, average linkage) of the WB1P tumors with tumors derived from published mouse models of luminal (WapCre;Cdh1F/F;PtenF/F, WEP; ref. 25) and basal-like (K14Cre;Brca1F/F;Trp53F/F, KB1P; ref. 20) breast cancer, using a three-genes signature that distinguishes the PAM50 subtypes26